MedTrace Logo

Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

NCT06937788 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2025-08-21

No results posted yet for this study

Summary

The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).

Conditions

Interventions

DRUG

Upadacitinib

30 mg tablet daily

BIOLOGICAL

Dupilumab

300 mg injection every other week

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Jochen M Schmitt · Center for Evidence-based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-02
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06937788 on ClinicalTrials.gov